Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors With the Clinical Application of FAPI Imaging?
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Apr 2023
01 Apr 2023
Historique:
pubmed:
9
2
2023
medline:
4
3
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Studies with [ 68 Ga]Ga-labeled or [ 18 F]F-labeled fibroblast activation protein inhibitor compounds have demonstrated favorable characteristics for PET/CT imaging, making them especially interesting for digestive tumors. In this review, the recent evidence in this field and its potential clinical applications are discussed.
Identifiants
pubmed: 36754356
doi: 10.1097/RLU.0000000000004602
pii: 00003072-202304000-00006
doi:
Substances chimiques
Gallium Radioisotopes
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318-319Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging . 2015;42:328–354.
Delgado Bolton RC, Aide N, Colletti PM, et al. EANM guideline on the role of 2-[ 18 F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging . 2021;48:3286–3302.
Vaz SC, Adam JA, Delgado Bolton RC, et al. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[ 18 F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 [published correction appears in Eur J Nucl Med Mol Imaging 2022;49:3300–3301]. Eur J Nucl Med Mol Imaging . 2022;49:1386–1406.
Berghmans T, Lievens Y, Aapro M, et al. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): lung cancer. Lung Cancer . 2020;150:221–239.
Gómez León N, Aguado Bueno B, Herreros Pérez M, et al. Agreement between 18 F-FDG PET/CT and whole-body magnetic resonance compared with skeletal survey for initial staging and response at end-of-treatment evaluation of patients with multiple myeloma. Clin Nucl Med . 2021;46:310–322.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68 Ga-DOTA–conjugated somatostatin receptor targeting peptides and 18 F-DOPA [published correction appears in Eur J Nucl Med Mol Imaging 2017]. Eur J Nucl Med Mol Imaging . 2017;44:1588–1601.
Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177 Lu-labelled PSMA-ligands ( 177 Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging . 2019;46:2536–2544.
Brausi M, Hoskin P, Andritsch E, et al. ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol Hematol . 2020;148:102861.
Kömek H, Can C, Kaplan İ, et al. Comparison of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT and [ 18 F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging . 2022;49:3898–3909.
Kratochwil C, Flechsig P, Lindner T, et al. 68 Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med . 2019;60:801–805.
Chen H, Zhao L, Ruan D, et al. Usefulness of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [ 18 F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging . 2021;48:73–86.
Pang Y, Zhao L, Luo Z, et al. Comparison of 68 Ga-FAPI and 18 F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology . 2021;298:393–402.
Qin C, Song Y, Gai Y, et al. Gallium-68–labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging . 2022;49:4228–4240.
Kosmala A, Serfling SE, Schlötelburg W, et al. Impact of 68 Ga-FAPI-04 PET/CT on staging and therapeutic management in patients with digestive system tumors. Clin Nucl Med . 2023;48:35–42.
Wang H, Zhu W, Ren S, et al. 68 Ga-FAPI-04 versus 18 F-FDG PET/CT in the detection of hepatocellular carcinoma. Front Oncol . 2021;11:693640.
National Library of Medicine (US). (2022). Study of [68Ga]FAPI-46 PET in patients with pancreatic ductal carcinoma (FAPI-46 PDAC). Available at: https://clinicaltrials.gov/ct2/show/NCT05262855 . Accessed December 18, 2022.
National Library of Medicine (US). (2022). Study of [18F]FAPI-74 PET in patients with gastrointestinal cancers (18F-FAPI-74 GI). Available at: https://clinicaltrials.gov/ct2/show/NCT05641896 . Accessed December 18, 2022.
Delgado Bolton RC, Calapaquí Terán AK, Fanti S, et al. New biomarkers with prognostic impact based on multitracer PET/CT imaging in neuroendocrine neoplasms: the light leading out of the darkness in challenging tumors. Clin Nucl Med . 2022;47:219–220.
Delgado Bolton RC, Calapaquí Terán AK, Fanti S, et al. The concept of strength through synergy applied to the search of powerful prognostic biomarkers in gastroesophageal cancer: an example based on combining clinicopathological parameters, imaging-derived sarcopenia measurements, and radiomic features. Clin Nucl Med . 2023;48:156–157.